1. Introduction {#sec1-molecules-23-01071}
===============

*Ginkgo biloba* Extract (GBE), extracted from *Ginkgo biloba* leaves, is mainly composed of terpene trilactones, flavonoid heterosides, ginkgolic acids, phenolic acids, proanthocyanidins, etc. \[[@B1-molecules-23-01071],[@B2-molecules-23-01071]\]. GBE can significantly decrease serum ET-1 to reverse endothelial dysfunction \[[@B3-molecules-23-01071],[@B4-molecules-23-01071],[@B5-molecules-23-01071]\]. Nowadays, chromatographic fingerprint plays a vital role in the quality control of GBE, including for authenticity determination and chemical information analyses. However, existing GBE studies with fingerprint tech mainly focus on the chemical characteristics, but do not elaborate the correlation between compounds and their bioactive effects. Based on the hypothesis that bioactive effects varied with differences between compounds, chromatographic fingerprint and bioactive tests of nine re-combined GBE samples were conducted, and their correlations were further analyzed ([Figure 1](#molecules-23-01071-f001){ref-type="fig"}). Other than the usual methods of isolation, purification, and then biotests, this study provided a feasible approach for exploring the bioactive compounds in complex systems.

2. Results {#sec2-molecules-23-01071}
==========

2.1. GBE HPLC Fingerprint and Identification of Components {#sec2dot1-molecules-23-01071}
----------------------------------------------------------

With optimized HPLC conditions, the standard GBE HPLC fingerprint ([Figure 2](#molecules-23-01071-f002){ref-type="fig"}) was established, and 21 compounds were identified or characterized through the HPLC-DAD-ELSD-MS/MS technique in our previous work \[[@B6-molecules-23-01071]\] ([Table 1](#molecules-23-01071-t001){ref-type="table"}). According to the retention time, UV spectra, and MS spectra of the reference standards, Protocatechuic acid (P~4~), Rutin (P~12~), Ginkgolide A (P~24~), Ginkgolide B (P~25~), and Bilobalide (P~26~) were identified unambiguously. The other compounds were characterized according to MS fragmentation pattern, UV spectra, and the reported literature.

2.2. Three Portions Separated from GBE and Nine Re-Combined GBE Samples {#sec2dot2-molecules-23-01071}
-----------------------------------------------------------------------

Portion A, portion B, and portion C were separated from GBE via D101 macroporous resin. They were re-combined with different compositions to get the nine GBE samples ([Figure 3](#molecules-23-01071-f003){ref-type="fig"}). In accordance with the optimized HPLC conditions, the HPLC fingerprints of the nine GBE samples (S~1~--S~9~) were constructed ([Figure 4](#molecules-23-01071-f004){ref-type="fig"}). 26 peak areas in nine GBE samples are shown in [Table 2](#molecules-23-01071-t002){ref-type="table"}.

2.3. Cluster Analysis of Nine GBE Samples {#sec2dot3-molecules-23-01071}
-----------------------------------------

Based on the data of the 26 peak areas, Cluster analysis was performed in SPSS 19.0. The clustering method was Nearest Neighbor. The distance calculation method was Euclidean Distance. The rescaled distance cluster combine was defined as 5. Nine GBE samples could be divided into seven categories ([Figure 5](#molecules-23-01071-f005){ref-type="fig"}): S~2~ and S~5~ belonged to a class, S~3~ and S~6~ belonged to a class, and the remaining samples respectively represented a class each. Cluster analysis results indicated that the nine GBE samples had chemical differences in their compounds.

2.4. ET-1 Biotests of Nine GBE Samples {#sec2dot4-molecules-23-01071}
--------------------------------------

Plasma ET-1 in vivo was detected in the 11 treatment groups ([Table 3](#molecules-23-01071-t003){ref-type="table"}). Compared with the normal group, plasma ET-1 content significantly increased in the model group. Compared with the model group, plasma ET-1 content significantly decreased in the S1, S2, S3, S4, S5, S6, S8, and S9 groups, but not for the S7 group. Biotest results indicated that nine GBE samples showed biological differences for ET-1.

2.5. CA between Compound Differences and Biological Differences {#sec2dot5-molecules-23-01071}
---------------------------------------------------------------

Dimensionless data of the peak areas of 26 compounds and their ET-1 values are shown in [Table S1](#app1-molecules-23-01071){ref-type="app"}. The Pearson correlation coefficients (PCC) are shown in [Table 4](#molecules-23-01071-t004){ref-type="table"}. The results indicated that P~18~, P~22~, and P~23~ had a significantly positive relation with ET-1, but that P~1~, P~2~, P~3~, P~4~, and P~6~ were negatively correlated to ET-1.

The scores of the extracted C1 and C2 were used as the new independent variables ([Table 5](#molecules-23-01071-t005){ref-type="table"}). The strict regression equation between C1, C2 and ET-1 was established as follows: ET-1 = 94.68 + 0.678 × C1 + 2.626 × C2 (R = 0.801, Sig. \< 0.05).

In accordance with the rotated component matrix ([Table S3](#app1-molecules-23-01071){ref-type="app"}), C1 and C2 were replaced by the 26 original independent variables (P~1~--P~26~). Regression coefficients (RC) of P~1~--P~26~ are shown in [Table 6](#molecules-23-01071-t006){ref-type="table"}. The results were in accordance with the PC analysis, indicating that P~18~, P~20~, P~22~, P~23~, and P~24~ had a highly positive relation with ET-1, but that P~1~, P~2~, P~3~, P~4~, and P~6~ showed a negative correlation.

3. Discussion {#sec3-molecules-23-01071}
=============

Current research methods for natural medicine mainly fall into two directions. The first is to separate single components or the active part and then assess the biological effects in vivo or in vitro; the second is to match up the compounds and bio-effects in the whole herb using computational modelling. It is understood that separating and assessing each compound one by one is almost impossible. Numerous existing studies of GBE focus on the chemical identification and the biological effects, separately, but not the correlation between them. ET-1 is a potent vasoconstrictor peptide released from endothelial cells \[[@B7-molecules-23-01071]\]. Several studies have demonstrated that exposure to cold is associated with raised plasma ET-1 \[[@B8-molecules-23-01071],[@B9-molecules-23-01071]\]. Thus, a rat model combined with subcutaneous injection of adrenaline and ice-bath was established, and similar data was observed in the present study.

GBE's main bioactive constituents include flavonoid glycosides and terpene trilactones. Flavonoid glycosides were detected by HPLC-UV \[[@B10-molecules-23-01071],[@B11-molecules-23-01071],[@B12-molecules-23-01071]\]. Terpene trilactones were detected by Evaporative Light Scattering Detector (ELSD) due to their poor UV absorption property. Thus, GBE's chromatographic fingerprint was established by HPLC-UV-ELSD, in which 21 compounds were identified or characterized through the UFLC-DAD-Q-TOF-MS/MS technique. To prepare appropriate GBE samples with varying compounds, three portions were separated from GBE using D101 macroporous resin, and then re-combined to get nine GBE samples. The different ratios of the three portions were designed using a four-factor, nine-level Uniform Design (UD) method, which has been successfully applied to prepare different Chinese medicine samples \[[@B13-molecules-23-01071],[@B14-molecules-23-01071]\]. To guarantee the differences of the GBE samples, cluster analysis was conducted that nine GBE samples could be divided into seven categories.

Correlation analysis was applied to discover and predict the compounds with bioactivities in our previous work \[[@B15-molecules-23-01071],[@B16-molecules-23-01071]\]. The discovery of bioactive compounds was based on the hypothesis that the effect varies based on differences in the compounds. If a compound varies a little, while showing a big difference in the effect, the compound will be considered to have a close relevance; in the opposite case, the compound will be considered to have no effect contribution. In the cluster analysis, although S2 and S5, S3 and S6 belonged to a class, there were still relatively large differences among the discovered bioactive compounds, and this might be the reason behind the differences in effect among them. In this work, the Pearson Correlation and Multiple Linear Regression methods were used to evaluate the effect contribution of each compound, and the analysis results of the two methods were highly consistent. The connections between the identified compounds and ET-1 are presented dynamically in the electronic [supplementary material](#app1-molecules-23-01071){ref-type="app"} (Compound-effect bubble chart). Kaempferol-3-*O*-α-[l]{.smallcaps}-glucoside (P~18~), 3-*O*-{2-*O*-{6-*O*-\[P-OH-trans-cinnamoyl\]-β-[d]{.smallcaps}-glucosyl}-α-rhamnosyl} Quercetin isomers (P~22~), and 3-*O*-{2-*O*-{6-*O*-\[P-OH-trans-cinnamoyl\]-β-[d]{.smallcaps}-glucosyl}-α-rhamnosyl} Kaempferide (P~23~) were significantly correlated to ET-1 ([Figure 6](#molecules-23-01071-f006){ref-type="fig"}). Numerous preclinical studies provide support for flavonoids exhibiting protective effects on endothelial dysfunction \[[@B17-molecules-23-01071]\]. Quercetin, modified from quercetin flavonoid during metabolism, inhibits the overproduction and gene expression of ET-1 in vitro \[[@B18-molecules-23-01071],[@B19-molecules-23-01071]\]. Kaempferol can improve the endothelial damage \[[@B20-molecules-23-01071]\], but there is no direct evidence for either Kaempferol and Kaempferide on regulating ET-1. In GBE, not all the flavonoid glycosides have strong inhibitory activity on ET-1 release. As for terpene trilactones in GBE, Ginkgolide A and Ginkgolide B had a highly positive correlation, which also contributed to the effects. Moreover, P~1~, P~2~, P~3~, P~4~, and P~6~ from portion A were negatively correlated with ET-1. Despite having no statistical meaning, the results suggested that water-soluble constituents might induce endothelial dysfunction, but this needs further experiments to confirm.

4. Materials and Methods {#sec4-molecules-23-01071}
========================

4.1. Animals and Materials {#sec4dot1-molecules-23-01071}
--------------------------

Sprague-Dawley male rats, Specific pathogen-free, 250--300 g, were purchased from Guangdong Medical Laboratory Animal Center (SCXK-(Yue) 2013-0002). Rats were fed on standard laboratory diet and water and kept in environmentally controlled quarters with temperature maintained at 25 °C and a 12 h dark-light cycle for a week before use. Experiments were approved by the Animal Care and Use Committee of Sun Yat-sen University (2015062529) and performed in accordance with guidelines of Institutional Animal Care and Use Committee for U.S. institutions. GBE was manufactured by INDENA S.P.A (batch: 15271). GBE Injection, the sterile solution of GBE, was purchased from Yue Kang Pharmaceutical Group Co., Ltd. (batch: 05121108) (Beijing, China). Adrenalin (Adr) Hydrochloride Injection was purchased from Yuanda Medical (Harbin, China) Co., Ltd. (batch: 150412). 1,2-propanediol and absolute ethyl alcohol was purchased from Tianjin Fuyu Chemical Co., Ltd. (batch: 20141026) (Tianjin, China). Rat ET-1 Elisa Assay Kit was purchased from Nanjing Jiancheng Bioengineering Institute. D101 macroporous resin was purchased from Xi'an Butian Adsorption Materials Co., Ltd. (batch: 20140918) (Xi'an, China).

4.2. Preparation of GBE Samples {#sec4dot2-molecules-23-01071}
-------------------------------

GBE (315 mg) was separated into three portions via D101 macroporous resin (20 g), with the eluent of 550 mL purified water (Portion A); 100 mL ethanol (40%, *v*/*v*, Portion B), and 100 mL absolute ethyl alcohol (Portion C). Each portion was evaporated with a rotary evaporator and dissolved in 1,2-propanediol (25%, g/mL) to 30 mL for HPLC analysis. According to a four-factor, nine-level UD ([Table 7](#molecules-23-01071-t007){ref-type="table"}), three portions were re-combined to get nine GBE samples. GBE Samples were stored at 4 °C before use.

4.3. HPLC Fingerprint and Cluster Analysis {#sec4dot3-molecules-23-01071}
------------------------------------------

GBE analyses were performed on an UltiMate 3000 series Dual-Gradient Analytical LC System (Dionex, Thermo Fisher Scientific Inc., Waltham, MA, USA), equipped with DAD and ELSD. The HPLC-DAD-ELSD conditions were as follows \[[@B6-molecules-23-01071]\]: Chromatographic separation was carried out using an Agilent zorbax SB C18 column (4.6 mm × 250 mm, 5 μm) as an analytical column and a Dionex Acclaim Polar Advantage C18 column (3.0 mm × 50 mm, 3 μm) as a pretreatment column, and operated at 25 °C; Mobile phase consisted of acetonitrile (A), tetrahydrofuran (B), formic acid (C, 0.1%, *v*/*v*) with a multi-step gradient elution (A: 0--27 min: 10%→28%, 27--27.1 min: 28%→1%, 27.1--40 min: 1%→25%; B: 0--27 min: 0%→0%, 27--27.1 min: 0%→15%, 27.1--40 min: 15%→15%; C: 0--27 min: 90%→78%, 27--27.1 min: 72%→84%, 27.1--40 min: 84%→60%) at a flow rate of 1.0 mL/min; Drift tube temperature of ELSD was set at 50 °C, and the nebulizing gas pressure was 3.5 bar with a gain value of 11; Sample volume was set at 10 μL. Data were controlled by Chromeleon 6.8 chromatography data system. 26 peak areas in the HPLC fingerprint were used for Cluster Analysis in SPSS 19.0 (IBM, Armonk, NY, USA). The clustering method was Nearest Neighbor, and the distance calculation method was Euclidean Distance. The rescaled distance cluster combine was set at 5.

4.4. Modelling and ET-1 Assay {#sec4dot4-molecules-23-01071}
-----------------------------

Rats were randomly divided into eleven groups of normal (normal saline: NS, 7.2 mL/kg, *n* = 10) as blank, model (NS, 7.2 mL/kg, *n* = 10) as negative control, and nine GBE samples (7.2 mL/kg, *n* = 10), receiving intraperitoneal injection once daily for 7 consecutive days. After the 7th administration, the rats---except those in normal group---were subcutaneously injected with Adr (0.8 mg/kg). After 2 h, rats were kept in ice-water (0--2 °C) for 4 min, and 2 h later were subcutaneously re-injected with Adr (0.8 mg/kg). All the rats were fasted for 12 h. Blood was collected through abdominal aortic. Plasma ET-1 was detected by Elisa kit.

4.5. Correlation Analysis between Compound Difference and Bioactivity Difference {#sec4dot5-molecules-23-01071}
--------------------------------------------------------------------------------

*Pearson Correlation*. 26 Peak areas were regarded as independent variables (P~1~--P~26~). Average ET-1 value was regarded as a dependent variable. Every value of the peak areas and ET-1 in [Table 2](#molecules-23-01071-t002){ref-type="table"} was divided by the average of each column to get dimensionless data ([Table S1](#app1-molecules-23-01071){ref-type="app"}). Pearson Correlation was used to analyze the correlation among P~1~--P~26~ and ET-1. *Multiple Linear Regression*. 26 independent variables (P~1~--P~26~) were recombined into two mutual independent principal components, which were regarded as new independent variables (C1 and C2, contributing to 96.388% of the total variance, [Table S2](#app1-molecules-23-01071){ref-type="app"}). The regression equation between two components (C1 and C2) and ET-1 parameter was constructed by a stepwise regression analysis approach. Once a strict regression equation was established (*p* \< 0.05), C1 and C2 would be replaced by the 26 original independent variables (P~1~--P~26~) according to the rotated component matrix ([Table S3](#app1-molecules-23-01071){ref-type="app"}). Then, the regression coefficients of P~1~--P~26~ were used to evaluate the effect contribution.

4.6. Statistical Analysis {#sec4dot6-molecules-23-01071}
-------------------------

Experimental data were presented as mean ± standard deviation and analyzed by One-Way Analysis of Variance. *p*-values less than 0.05 or 0.01 were considered statistically significant.

5. Conclusions {#sec5-molecules-23-01071}
==============

Kaempferol-3-*O*-α-[l]{.smallcaps}-glucoside, 3-*O*-{2-*O*-{6-*O*-\[P-OH-trans-cinnamoyl\]-β-[d]{.smallcaps}-glucosyl}-α-rhamnosyl} Quercetin isomers, and 3-*O*-{2-*O*-{6-*O*-\[P-OH-trans-cinnamoyl\]-β-[d]{.smallcaps}-glucosyl}-α-rhamnosyl} Kaempferide were discovered to have the closest relevance to ET-1, which has not been reported so far and could provide further reference for the quality control and novel pharmaceutical development of GRE. Moreover, this work proposes a feasible approach for the discovery and prediction of compounds and their bioactivities in complex systems, especially for traditional Chinese medicine. The specific process is as follows: prepare the samples by the re-combination of different parts; establish the HPLC fingerprints; evaluate the bio-effects in vivo; regard the compound differences and effect differences as mathematical variables; analyze the relevance between the variables to find key bioactive compounds.
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The following are available online at <http://www.mdpi.com/1420-3049/23/5/1071/s1>, Table S1: The dimensionless data of 26 peak areas and parameter ET-1 values; Table S2: The total variance explained of two Components; Table S3: The rotated component matrix; Compound-effect bubble chart.
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###### 

Identification of 21 compounds in GBE HPLC fingerprint by UFLC-DAD-Q-TOF-MS/MS.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Peaks   Retention Time   Major Fragment Ions (MS/MS)        Identified Compounds
  ------- ---------------- ---------------------------------- ---------------------------------------------------------------------------------------------------------
  P~1~    2.520                                               \-

  P~2~    3.840                                               \-

  P~3~    5.670                                               \-

  P~4~    6.960            137.0235 \[M + H-H~2~O\]^+^,\      Protocatechuic acid ^a^
                           109.028 \[M + H-H~2~O-CO\]^+^,\    
                           93.0348 \[M + H-H~2~O-CO~2~\]^+^   

  P~5~    9.403                                               \-

  P~6~    10.617                                              \-

  P~7~    14.367           611.1586 \[M + H-rha\]^+^,\        3-*O*-\[2-*O*,6-*O*-double(α-[l]{.smallcaps}-rhamnosyl)-β-[d]{.smallcaps}-glucosyl\] Quercetin
                           465.1014 \[M + H-2rha\]^+^,\       
                           303.0496 \[M + H-2rha-glu\]^+^     

  P~8~    15.207           319.0444 \[M + H-rha-glu\]^+^      3-*O*-\[6-*O*-(α-[l]{.smallcaps}-rhamnosyl)-β-[d]{.smallcaps}-glucosyl\] Myricetin

  P~9~    15.607           319.0454 \[M + H-glu\]^+^          3-*O*-\[β-[d]{.smallcaps}-glucosyl\] Myricetin

  P~10~   16.420           595.1643 \[M + H-rha\]^+^,\        3-*O*-\[2-*O*,6-*O*-double(α-[l]{.smallcaps}-rhamnosyl)-β-[d]{.smallcaps}-glucosyl\] Kaempferide
                           449.1073 \[M + H-2rha\]^+^,\       
                           287.0552 \[M + H-2rha-glu\]^+^     

  P~11~   16.613           625.174 \[M + H-rha\]^+^,\         3-*O*-\[2-*O*,6-*O*-double(α-[l]{.smallcaps}-rhamnosyl)-β-[d]{.smallcaps}-glucosyl\] Isorhamnetin
                           479.1167 \[M + H-2rha\]^+^,\       
                           317.0650 \[M + H-2rha-glu\]^+^,    

  P~12~   18.233           465.1012 \[M + H-rha\]^+^\         3-*O*-\[6-*O*-(α-[l]{.smallcaps}-rhamnosyl)-β-[d]{.smallcaps}-glucosyl\] Quercetin (rutin) ^a^
                           303.0496 \[M + H-rha-glu\]^+^,     

  P~13~   18.813           495.1122 \[M + H-rha\]^+^,\        3-*O*-\[6-*O*-(α-[l]{.smallcaps}-rhamnosyl)-[d]{.smallcaps}-glucosyl\] Queretagetin
                           333.0600 \[M + H-glu-rha\]^+^      

  P~14~   19.720           303.0501 \[M + H-glu\]^+^          Quercetin-3-*O*-β-[d]{.smallcaps}-glucoside

  P~15~   20.807           303.0501 \[M + H-rha-glu\]^+^      3-*O*-\[2-*O*-(β-[d]{.smallcaps}-glucosyl)-α-[l]{.smallcaps}-rhamnosyl\] Quercetin

  P~16~   21.173           287.0546 \[M + H-rha-glu\]^+^      3-*O*-\[6-*O*-(β-[d]{.smallcaps}-glucosyl)-α-[l]{.smallcaps}-rhamnosyl\] Kaempferide

  P~17~   21.693           479.1176 \[M + H-rha\]^+^,\        3-*O*-\[6-*O*-(β-[d]{.smallcaps}-glucosyl)-α-[l]{.smallcaps}-rhamnosyl\] Isorhamnetin
                           317.0658 \[M + H-rha-glu\]^+^      

  P~18~   22.790           287.055 \[M + H-glu\]^+^           Kaempferol-3-*O*-α-[l]{.smallcaps}-glucoside

  P~19~   23.057           347.0761 \[M + H-rha-glu\] +       3-*O*-\[6-*O*-(α-[l]{.smallcaps}-rhamnosyl)-β-[d]{.smallcaps}-glucosyl\] Syringetin

  P~20~   23.487           347.0767 \[M + H-rha-glu\] +       3-*O*-\[2-*O*-(α-[l]{.smallcaps}-rhamnosyl)-β-[d]{.smallcaps}-glucosyl\] Syringetin

  P~21~   23.867           287.0569 \[M + H-rha-glu\]^+^      3-*O*-\[2-*O*-(β-[d]{.smallcaps}-glucosyl)-α-[l]{.smallcaps}-rhamnosyl\] Kaempferide

  P~22~   26.527           449.101 \[M + H-rha-glu\]^+^,      3-*O*-{2-*O*-{6-*O*-\[P-OH-trans-cinnamoyl\]-β-[d]{.smallcaps}-glucosyl}-α-rhamnosyl} Quercetin isomers

  P~23~   29.233           433.1063 \[M + H-rha-glu\]^+^,     3-*O*-{2-*O*-{6-*O*-\[P-OH-trans-cinnamoyl\]-β-[d]{.smallcaps}-glucosyl}-α-rhamnosyl} Kaempferide

  P~24~   34.379           391.1396 \[M + H-H~2~O\]^+^;\      Ginkgolide A ^a^
                           373.1075 \[M + H-2H~2~O\]^+^,\     
                           345.13 \[M + H-2H~2~O-CO\]^+^,     

  P~25~   35.195           407.1368 \[M + H-H~2~O\]^+^,\      Ginkgolide B ^a^
                           389.1262 \[M + H-2H~2~O\]^+^,\     
                           361.1304 \[M + H-2H~2~O-CO\]^+^,   

  P~26~   22.296           309.3054 \[M + H-H~2~O\]^+^        Bilobalide ^a^
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ Identification in comparison with reference standards.

molecules-23-01071-t002_Table 2

###### 

The 26 peak areas of the nine GBE samples.

  Samples       P~1~        P~2~        P~3~        P~4~        P~5~        P~6~        P~7~        P~8~        P~9~        P~10~       P~11~       P~12~       P~13~
  ------------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  S~1~          1.2622      1.3788      2.1911      12.1766     2.8357      3.524       6.5859      2.0551      1.4858      8.3926      5.1951      28.4887     7.0591
  S~2~          3.1069      3.3891      5.7438      26.3239     2.0025      3.6599      3.8695      1.1924      0.801       4.7887      3.0219      17.4548     4.1193
  S~3~          5.1957      5.5726      9.7592      42.5976     1.0266      3.213       0           0           0           0           0           4.356       1.0038
  S~4~          0           0           0           9.8952      3.9214      4.981       9.2285      2.8734      2.0094      11.422      6.9621      37.5392     8.7436
  S~5~          3.2118      3.5892      5.5843      27.3079     2.991       4.6368      5.9836      1.8489      1.3209      7.3954      4.4638      24.571      5.7354
  S~6~          7.4305      6.3609      10.8327     48.0321     1.7808      4.3221      0           0           0           0           0           8.5261      1.9302
  S~7~          0           0           0           6.0996      5.5958      5.3295      12.8322     4.5302      3.3714      17.5349     10.0728     52.8165     12.5493
  S~8~          3.5617      3.7739      6.3758      28.8564     4.426       5.4215      9.0171      3.2387      2.2417      11.871      6.9002      36.2443     8.6628
  S~9~          9.3721      7.5017      13.1006     57.1505     3.0606      5.2422      4.1496      1.4944      1.0327      5.3503      3.1294      15.863      3.8046
  **Samples**   **P~14~**   **P~15~**   **P~16~**   **P~17~**   **P~18~**   **P~19~**   **P~20~**   **P~21~**   **P~22~**   **P~23~**   **P~24~**   **P~25~**   **P~26~**
  S~1~          9.4772      8.1063      23.5872     35.2178     3.0655      0.6415      1.9176      8.2878      25.8635     15.4303     4.9291      1.8927      18.2607
  S~2~          6.4263      5.2957      16.7922     24.4355     2.3935      0.4798      1.5539      5.2362      19.9002     12.9111     3.7011      1.1571      13.0276
  S~3~          2.6031      1.9266      8.5073      11.4559     1.587       0           1.0682      3.2834      14.0843     10.6601     5.6539      1.8087      7.1442
  S~4~          11.5354     10.171      27.3343     41.7826     3.0651      0.5678      1.9455      8.7336      25.4447     14.135      2.9817      0.4018      19.4095
  S~5~          7.8271      6.8175      18.9692     28.6363     2.2589      0.4425      1.4746      5.2605      17.9486     10.0593     2.0966      0.1254      10.8716
  S~6~          3.2396      2.6844      8.7539      12.6152     1.2919      0           0           2.8117      10.7481     7.2251      0           0           6.5011
  S~7~          15.3825     13.8241     33.6609     52.7184     3.4513      0.7236      2.1981      9.7774      25.1843     10.9571     2.0016      0.3504      23.2875
  S~8~          10.5258     9.4589      22.7495     35.6553     2.3213      0.5586      1.443       5.3602      16.1803     5.931       0.7501      0.3917      14.6142
  S~9~          4.4374      4.0615      9.2461      14.7265     0           0           0           2.0158      5.1178      1.4163      0           0           5.2694

molecules-23-01071-t003_Table 3

###### 

The content of ET-1 in plasma.

  Group    ET-1 (ng/L)
  -------- ----------------------
  Normal   93.07 ± 5.45
  Model    107.07 ± 8.50 ^\#\#^
  S1       96.15 ± 11.45 \*
  S2       95.72 ± 8.88 \*
  S3       97.40 ± 15.21 \*
  S4       96.30 ± 9.68 \*
  S5       93.89 ± 6.76 \*\*
  S6       94.16 ± 8.49 \*\*
  S7       99.37 ± 12.65
  S8       90.82 ± 10.19 \*\*
  S9       88.31 ± 7.19 \*

^\#\#^*p* \< 0.01 when compared with normal. \* *p* \< 0.05 and \*\* *p* \< 0.01 when compared with model.

molecules-23-01071-t004_Table 4

###### 

PCCs between 26 components and ET-1.

  Variables   PCC      Variables   PCC        Variables   PCC
  ----------- -------- ----------- ---------- ----------- ------------
  P1          −0.598   P10         0.209      P19         0.406
  P2          −0.658   P11         0.214      P20         0.647
  P3          −0.651   P12         0.277      P21         0.635
  P4          −0.658   P13         0.273      P22         0.731 \*
  P5          0.046    P14         0.365      P23         0.806 \*\*
  P6          −0.414   P15         0.332      P24         0.652
  P7          0.198    P16         0.461      P25         0.474
  P8          0.167    P17         0.424      P26         0.577
  P9          0.198    P18         0.727 \*               

Note: \* *p* \< 0.05 and \*\* *p* \< 0.01.

molecules-23-01071-t005_Table 5

###### 

The scores of two components C1 and C2.

  Samples   C1       C2
  --------- -------- --------
  S~1~      0.055    1.411
  S~2~      −0.501   0.768
  S~3~      −1.484   0.772
  S~4~      0.828    0.533
  S~5~      0.055    −0.118
  S~6~      −1.011   −0.770
  S~7~      1.739    0.011
  S~8~      0.775    −0.787
  S~9~      −0.456   −1.820

molecules-23-01071-t006_Table 6

###### 

RC between 26 components and ET-1 (Model Sig. \< 0.05).

  Variables   RC       Variables   RC      Variables   RC
  ----------- -------- ----------- ------- ----------- -------
  P~1~        −2.297   P~10~       0.777   P~19~       1.779
  P~2~        −2.127   P~11~       0.851   P~20~       2.292
  P~3~        −2.127   P~12~       0.902   P~21~       2.019
  P~4~        −2.202   P~13~       0.921   P~22~       2.445
  P~5~        0.127    P~14~       1.196   P~23~       2.637
  P~6~        −1.362   P~15~       1.081   P~24~       2.259
  P~7~        0.822    P~16~       1.522   P~25~       1.913
  P~8~        0.649    P~17~       1.395   P~26~       1.860
  P~9~        0.675    P~18~       2.291               

molecules-23-01071-t007_Table 7

###### 

Volumes and percentage of three portions in nine GBE samples.

  Sample   Portion A mL (% ^a^)   Portion B mL (%)   Portion C mL (%)
  -------- ---------------------- ------------------ ------------------
  S~1~     2.50 (50)              7.50 (150)         10.00 (200)
  S~2~     6.25 (125)             3.75 (75)          8.75 (175)
  S~3~     10.00 (200)            0 (0)              7.50 (150)
  S~4~     1.25 (25)              8.75 (175)         6.25 (125)
  S~5~     5.00 (100)             5.00 (100)         5.00 (100)
  S~6~     8.75 (175)             1.25 (25)          3.75 (75)
  S~7~     0 (0)                  10.00 (200)        2.50 (50)
  S~8~     3.75 (175)             6.25 (125)         1.25 (25)
  S~9~     7.50 (150)             2.50 (50)          0 (0)

Note: ^a^ % represents the nine levels (0, 25%, 50%, 75%, 100%, 125%, 150%, 175%, 200%) of each portion A, B, C, and the sequence was designed according to a four-factor, nine-level UD method.

[^1]: These authors contributed equally to this paper.
